Clinical Trial Update: Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) [Phase 1]

View source ↗

Summary

Exelixis reports that the QUARTZ-101 Phase 1 trial of XL102 as a single agent and in combination therapy for solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer Hormone Receptor-positive
• Castration-resistant Prostate Cancer
• Ovarian Epithelial Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• XL102

Snippet

Sponsor: Exelixis | Conditions: Neoplasm Malignant, Epithelial Ovarian Cancer | Phase 1 | Status: TERMINATED